Benzinga | Oct 1, 2021 12:40PM EDT

Morgan Stanley Downgrades Acceleron Pharma to Equal-Weight, Announces $180 Price Target

Morgan Stanley analyst Jeffrey Hung downgrades Acceleron Pharma (NASDAQ:XLRN) from Overweight to Equal-Weight and announces $180 price target.